Zeven (dalbavancin) / RaQualia, AbbVie - LARVOL DELTA

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia (clinicaltrials.gov) - P1 | N=29 | Recruiting | Sponsor: St. Jude Children's Research Hospital | Suspended ➔ Recruiting | Trial completion date: Sep 2030 ➔ Sep 2031 | Trial primary completion date: Sep 2028 ➔ Sep 2030

Enrollment open • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Oncology

Dalbavancin as chronic suppressive therapy in a patient with aortic vascular prosthesis due to CA-MRSA and a severe renal failure (ESCMID Global 2026) - No abstract available

Clinical • Renal Disease

Dalbavancin use in vascular graft infections: a report of three cases (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

The 101 Dalbatians: a descriptive analysis of clinical features, microbiology, and outcomes of TDM-guided dalbavancin therapy in osteoarticular infections (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Fluorescent/dalbavancin improves imaging of implant-associated osteomyelitis (ESCMID Global 2026) - No abstract available

Inflammation

Long-term (> one year) suppressive therapy with dalbavancin in a tertiary care hospital (ESCMID Global 2026) - No abstract available

Clinical

Role of the WTA biosynthesis gene tarA in dalbavancin resistance in Staphylococcus aureus (ESCMID Global 2026) - No abstract available

Subinhibitory concentrations of cefadroxil delay or prevent dalbavancin resistance and alter mutational pathways in S. aureus (ESCMID Global 2026) - No abstract available

Profiling of dalbavancin resistance in clinical MRSA through a nationwide genomic survey in China: insights into resistance mechanisms (ESCMID Global 2026) - No abstract available

Clinical

Economic outcomes with dalbavancin vs standard of care in complicated Staphylococcus aureus bacteraemia: findings from the DOTS trial (ESCMID Global 2026) - No abstract available

HEOR

Optimising dalbavancin therapy: bayesian TDM insights for extending dosing intervals (ESCMID Global 2026) - No abstract available

Optimising dalbavancin long-term therapy: a hybrid machine learning and population pharmacokinetic strategy for personalised dosing (ESCMID Global 2026) - No abstract available

Clinical • Machine learning • PK/PD data

Toward model informed precision dosing for Dalbavancin (ESCMID Global 2026) - No abstract available

Off-label use of dalbavancin for osteoarticular infections and deep surgical site infections in children and adolescents: experience from a paediatric Italian tertiary care hospital (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pediatrics

Pharmacokinetics of dalbavancin in complicated Staphylococcus aureus bacteraemia (ESCMID Global 2026) - No abstract available

PK/PD data

Beyond soft tissue infections: dalbavancin as a promising option for spondylodiscitis, osteomyelitis, and implant-related infections (ESCMID Global 2026) - No abstract available

Infectious Disease • Inflammation

In vivo dalbavancin efficacy against two different methicillin-resistant Staphylococcus epidermidis (MRSE) strains in an experimental endocarditis model (ESCMID Global 2026) - No abstract available

Preclinical • Cardiovascular

Partial oral vs dalbavancin for outpatient treatment of infective endocarditis: experience in a reference centre (ESCMID Global 2026) - No abstract available

Clinical • Cardiovascular

Clinical experience with dalbavancin for the treatment of skin and soft tissue infections in vulnerable patient populations (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Proportion and antibiogram of methicillin-resistant Staphylococcus aureus (MRSA) in Africa: a systematic review and meta-analysis. (PubMed, Antimicrob Resist Infect Control) - "The proportion of MRSA in Africa remains high at 42.2%, with marked regional disparities. Although resistance rates for linezolid and vancomycin are relatively low, they surpass global averages, raising concerns about emerging resistance. Alarmingly high resistance rates to several other antibiotics further underscore the urgent need for targeted interventions and continuous surveillance."

Journal • Retrospective data • Infectious Disease

Battling biofilms: evaluating selected agents against Cutibacterium acnes-a review. (PubMed, PeerJ) - "Clinical trials demonstrated that dalbavancin reduced biofilm formation while niosomes effectively decreased inflammation in acne lesions...The review examines a range of effective agents and explores their potential applications in acne management, offering valuable insights for clinicians-especially dermatologists-seeking to optimize patient care. In addition, this review provides an understanding about the different agents and their antibiofilm properties that enable researchers to develop effective therapeutic approaches against C. acnes biofilm-related infectious diseases for the benefit of human health."

Journal • Review • Acne Vulgaris • Dermatology • Infectious Disease • Inflammation

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia (clinicaltrials.gov) - P1 | N=29 | Suspended | Sponsor: St. Jude Children's Research Hospital | Recruiting ➔ Suspended

Trial suspension • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Neutropenia • Oncology

EFFECTIVENESS AND SAFETY OF DALBAVANCIN IN INFECTIVE ENDOCARDITIS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data • Review • Cardiovascular

Real world use of dalbavancin for bone and joint infections: a retrospective case series in adults and children. (PubMed, BMC Res Notes) - No abstract available

Journal • Real-world evidence • Retrospective data • Infectious Disease • Inflammation

A bundle of the top 10 OPAT publications in 2024. (PubMed, Antimicrob Steward Healthc Epidemiol) - "This article summarizes the top 10 OPAT articles published in 2024, based on those survey results. Common themes from the top 10 OPAT articles published in 2024 included OPAT clinician workload, patient perspectives of OPAT, tools for OPAT work, and dalbavancin use."

Journal • Review • Infectious Disease